0000000001218536

AUTHOR

A.k. Burroughs

showing 11 related works from this author

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

Coagulation and fibrosis in chronic liver disease.

2008

In the hepatic tissue repair mechanism, hepatic stellate cells (HSCs) are recruited at the site of injury and their changes reflect paracrine stimulation by all neighbouring cell types, including sinusoidal endothelial cells, Kupffer cells, hepatocytes, platelets and leucocytes. Thrombin converts circulating fibrinogen to fibrin, promotes platelet aggregation, is a potent activator of endothelial cells, acts as a chemoattractant for inflammatory cells and is a mitogen and chemoattractant for fibroblasts and vascular smooth muscle cells. Most of the cellular effects elicited by thrombin are mediated via a family of widely expressed G-protein-coupled receptors termed protease activated recept…

Liver CirrhosisMaleKupffer CellsReceptors Proteinase-ActivatedThrombin liver fibrosisProteinase-ActivatedChronic liver diseaseFibrinLiver diseaseThrombinFibrosisReceptorsHepatic Stellate CellsmedicineAnimalsHumansPlateletReceptorBlood CoagulationWound HealingAnimals; Anticoagulants; Blood Coagulation; Chronic Disease; Disease Progression; Endothelial Cells; Female; Hepatic Stellate Cells; Hepatocytes; Humans; Kupffer Cells; Liver Cirrhosis; Liver Diseases; Male; Rats; Receptors Proteinase-Activated; Receptors Thrombin; Thrombin; Wound Healing; Gastroenterologybiologybusiness.industryLiver DiseasesThrombinGastroenterologyAnticoagulantsEndothelial Cellsmedicine.diseaseRatsChronic DiseaseImmunologyDisease ProgressionHepatocytesbiology.proteinHepatic stellate cellCancer researchFemaleReceptors Thrombinbusinessmedicine.drug
researchProduct

Transient elastography vs. platelets or APRI score to assess fibrosis in chronic hepatitis C

2008

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryFibrosisInternal medicineGastroenterologymedicinePlateletbusinessTransient elastographymedicine.diseaseGastroenterologyDigestive and Liver Disease
researchProduct

Fibrosis staging in chronic hepatitis C: Analysis of discordance between transient elastography and liver biopsy

2009

Summary.  In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir ≥ F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutive hepatitis C virus (HCV)-RNA positive patients had biochemical tests, TE and a biopsy performed on the same day. The Dale model was used to identify the variables associated with discordance between biopsy and elastography results. In 97 patients (34.2%), TE and histological assessment were discordant. Seventy-six of 286 (26.6%) had stage ≥F2 and TE < 7.1 kPa (false negat…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisTransient elastographyHepatitis C virusBiopsyLiver fibrosismedicine.disease_causeGastroenterologySeverity of Illness IndexAminotranferases; Liver fibrosis; Transient elastography; Adult; Diagnostic Errors; Female; Hepatitis C Chronic; Histocytochemistry; Humans; Liver Cirrhosis; Male; Middle Aged; ROC Curve; Transaminases; Biopsy; Elasticity Imaging Techniques; Severity of Illness Index; Hepatology; Infectious Diseases; Virology; Medicine (all)Liver diseaseInternal medicineVirologyBiopsymedicineHumansDiagnostic ErrorsChronicAminotranferases liver fibrosis transient elastographyTransaminasesmedicine.diagnostic_testReceiver operating characteristicHepatologybusiness.industryHistocytochemistryMedicine (all)Hepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CInfectious DiseasesROC CurveLiver biopsyAminotranferasesElasticity Imaging TechniquesFemaleTransient elastographybusiness
researchProduct

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.

2010

Summary. Background: Prothrombin time (PT) and the international normalized ratio (INR) are still routinely measured in patients with liver cirrhosis to ‘assess’ their bleeding risk despite the lack of correlation with the two. Thrombin generation (TG) assays are global assays of coagulation that are showing promise in assessing bleeding and thrombosis risks. Aim: To study the relationship between the INR and TG profiles in cirrhosis-induced coagulopathy. Methods: Seventy-three patients with cirrhosis were studied. All TG parameters were compared with those from a normal control group. Contact activation was prevented using corn trypsin inhibitor. TG was also assayed in the presence of Prot…

MaleRiskmedicine.medical_specialtyPathologyCirrhosisHemorrhageGastroenterologyThrombin generationLag timeFibrinolytic AgentsInternal medicinemedicineCoagulopathyHumansIn patientInternational Normalized RatioBlood CoagulationAgedbusiness.industryThrombinAnticoagulantsHematologyBlood Coagulation DisordersMiddle Agedmedicine.diseaseThrombosisFibrosisCoagulationLiverIntercellular Signaling Peptides and ProteinsFemalebusinessPeptidesProtein Cmedicine.drugProtein CJournal of thrombosis and haemostasis : JTH
researchProduct

Error factors for transient elastography in chronic hepatitis C

2008

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologymedicineTransient elastographybusinessGastroenterologyDigestive and Liver Disease
researchProduct

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis.

2015

SummaryBackground It is unclear whether the course of cirrhosis and its prognosis are related to the amount of collagen in the liver. Aim To determine whether fibrosis, assessed by collagen proportionate area (CPA) in patients with compensated cirrhosis, is associated with the presence of oesophageal varices, and predict disease decompensation during the follow-up period. Methods We prospectively evaluated 118 consecutive patients with compensated cirrhosis to correlate fibrosis, assessed by CPA in liver biopsies, with the presence of oesophageal varices (OV) and with the rate of liver decompensation (LD) development during a median follow-up of 72 months. Results At baseline 38 (32.2%) pat…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBiopsyEsophageal and Gastric VaricesGastroenterologySeverity of Illness IndexSex FactorsFibrosisInternal medicineHypertension PortalmedicineHumansPharmacology (medical)DecompensationProspective StudiesAgedHepatologyReceiver operating characteristicbusiness.industryProportional hazards modelGastroenterologyAge FactorsHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisFibrosisCPAROC CurvePortal hypertensionFemaleCollagenbusinessVaricesLiver FailureAlimentary pharmacologytherapeutics
researchProduct

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

Models for non-alcoholic fatty liver disease: a link with vascular risk.

2008

Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which express histological steatosis or steatohepatitis with fibrosis have been described. This review identifies those models of NAFLD with features of vascular risk.

medicine.medical_specialtyDiseasedigestive systemGastroenterologyInsulin resistanceNAFLD central obesity dyslipidaemia insulin resistance/type 2Risk FactorsInternal medicineDrug DiscoveryAnimalsHumansMedicineVascular DiseasesRisk factorPharmacologybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseasedigestive system diseasesFatty LiverDisease Models AnimalEndocrinologyInflammation MediatorsSteatosisMetabolic syndromeSteatohepatitisbusiness
researchProduct

Budd-Chiari syndrome with portal, splenic, and superior mesenteric vein thrombosis treated with TIPS: who dares wins.

2003

A 20 year old man presented with severe ascites and malnutrition due to Budd-Chiari syndrome (BCS) with portal vein (PV), and splenic and mesenteric vein (SMV) thrombosis in the proximal 3 cm. He had received regular and more frequent paracenteses of up to 17 litres each for eight months. He had a poor BCS prognostic index of 8.41 (table 1). After referral, despite full anticoagulation and diuretic drugs, he deteriorated over three weeks. No thrombophilic disorder was found. View this table: Table 1 Comparison of laboratory and clinical data before and two months after transjugular intrahepatic portosystemic stent shunt (TIPS) He underwent transjugular intrahepatic portosystemic stent shunt…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentBudd-Chiari SyndromeMesenteric VeinAscitesmedicineHumansSuperior mesenteric veinVenous Thrombosisbusiness.industryGastroenterologyGut Filemedicine.diseaseThrombosisSurgeryVenous thrombosisSplenic veinBudd–Chiari syndromeRadiologymedicine.symptomPortasystemic Shunt Transjugular IntrahepaticbusinessTransjugular intrahepatic portosystemic shuntFollow-Up StudiesGut
researchProduct

Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?

2008

Muscle cramps are a common and recurring symptom in patients with cirrhosis. Although, the pathophysiology has not been specifically studied in cirrhosis, this is thought to be the same for cramps in general, originating in the motorneurone, with high frequency firing of motor unit action potentials. However precise pathophysiological mechanisms are not known. Risk factors in cirrhosis have been little studied. Neither aetiology, nor pre-ascitic or ascitic stage, nor electrolyte disturbances, nor use of diuretic therapy has been found to have a statistical association with cramps in patients with cirrhosis. Effective treatments, from this literature review, are albumin, which however is exp…

CirrhosiQuinineCramp
researchProduct